Bruno Farmaceutici operates in Italy through a sales network of almost 140 representatives, targeting both primary care physicians and specialists such as orthopaedics, cardiologists, rheumatologists, physiatrists, geriatricians, internists, endocrinologists, ENT doctors, oncologists, pain therapists, diabetologists, nutrition and obesity specialists, infectious disease specialists, and toxicologists. The group also has a second sales network covering local pharmacies.
In 2012, pursuing its expansion mission, Bruno Farmaceutici also acquired Safilens. The acquisition was part of the diversification and internationalization approach recently adopted by the group. Safilens was founded in 2001 with the purpose of creating innovative, high-quality contact lenses. This is a solid, innovative company which has always been able to evolve in line with the market and the needs of contact lens users, and whose top strength is the excellence of its R&D department.
This acquisition brought Bruno Farmaceutici into the contact lens market, which has strong growth potential. In addition, Safilens can now tap into Bruno’s scientific know-how and valuable pharmaceutical R&D.